The translocations of MYC and BCL2 and/or BCL6 in patients with high-grade B-cell lymphomas remained a significant independent predictor of a poorer PFS and OS (Oki et al., 2014; Petrich et al., 2014), but the standard of care for these patients has not been established. The gene discussed is BCL2; the disease is B-cell non-Hodgkin lymphoma.